

Millendo Therapeutics, Inc. Logo

Millendo Therapeutics to Present at Upcoming Investor Conferences

March 5, 2020

ANN ARBOR, Mich.--(BUSINESS WIRE)-- [Millendo Therapeutics, Inc.](#) (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, and company management will participate in the following healthcare investor conferences:

32nd Annual ROTH Conference

Panel Presentation

Date and Time: March 16, 2020 at 12:00 p.m. PST

Location: Dana Point, CA

Oppenheimer & Co. 30th Annual Healthcare Conference

Corporate Presentation

Date and Time: March 18, 2020 at 2:45 p.m. EST

Location: New York, NY

A live webcast of the Oppenheimer presentation will be available on the Investors & Media section of Millendo's website at <http://investors.millendo.com>. A replay of the webcast will be archived on Millendo's website for 30 days following the presentation.

About Millendo Therapeutics, Inc.

Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit www.millendo.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200305005088/en/): <https://www.businesswire.com/news/home/20200305005088/en/>

Millendo Investor Contact:

Stephanie Ascher

Stern Investor Relations

212-362-1200

stephanie.ascher@sternir.com

Millendo Media Contact:

Julie Bane

MacDougall

617-821-1089

jbane@macbiocom.com

Source: Millendo Therapeutics, Inc.